Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Free Cash Flow (2016 - 2025)

Catalyst Pharmaceuticals' Free Cash Flow history spans 16 years, with the latest figure at $44.9 million for Q4 2025.

  • For Q4 2025, Free Cash Flow fell 36.63% year-over-year to $44.9 million; the TTM value through Dec 2025 reached $208.6 million, down 12.81%, while the annual FY2025 figure was $208.6 million, 12.81% down from the prior year.
  • Free Cash Flow reached $44.9 million in Q4 2025 per CPRX's latest filing, up from $32.4 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $72.6 million in Q3 2024 to a low of $2.9 million in Q1 2021.
  • Average Free Cash Flow over 5 years is $38.3 million, with a median of $36.3 million recorded in 2022.
  • Peak YoY movement for Free Cash Flow: tumbled 59.75% in 2021, then surged 192.04% in 2022.
  • A 5-year view of Free Cash Flow shows it stood at $19.1 million in 2021, then surged by 109.44% to $40.1 million in 2022, then soared by 38.62% to $55.6 million in 2023, then rose by 27.42% to $70.8 million in 2024, then plummeted by 36.63% to $44.9 million in 2025.
  • Per Business Quant, the three most recent readings for CPRX's Free Cash Flow are $44.9 million (Q4 2025), $32.4 million (Q3 2025), and $71.3 million (Q2 2025).